Background: Descriptive data on Pneumocystis jirovecii pneumonia (PJP) in solid
| ME THODS

| Study design and objectives
The STCS is a prospective national cohort, in which all SOTr in Switzerland, who sign a written informed consent are registered, representing >95% of SOTr. 16 Transplant activity is shared between six main institutions: all centers perform kidney transplants, whereas heart, liver, lung and pancreas transplants are performed in three (Bern, Lausanne and Zürich), three (Bern, Geneva and Zürich), two (Lausanne and Zürich) and two (Geneva and Zürich) centers, respectively. We performed an observational retrospective cohort study to describe the incidence, risk factors, and outcomes of PJP in this multicenter cohort of SOTr. All consecutive adult (≥18 years) patients who received a first SOT (heart, kidney, liver, lung, pancreas, or combined) between 01.05.2008 and 01.05.2016 were included in this study. Patients were censored for death, graft loss, loss-tofollow-up, or consent withdrawal. For patients without a censoring event, a minimum 6-month follow-up post-SOT was required for study inclusion. Patients were excluded if they received pancreatic islets or small bowel or had >1 SOT during the study period.
| Pneumocystis prophylaxis
Although Pneumocystis-prophylaxis guidelines are not universal in Switzerland, prophylaxis is generally provided for 12 months to lifelong in lung recipients, 6 months in heart and kidney transplant recipients, and in case of severe immunosuppression for liver recipients. In case of rejection episodes, treatment with thymoglobulin or intensification of immunosuppression and/or CMV infection/disease prophylaxis is further prolonged.
| Data collection
Data collection was performed in a two-step approach. All patients were identified using the STCS database. The following data were directly retrieved from the database: (a) 
| Definitions
PJP diagnosis was based on consensus guidelines, requiring a positive direct microscopy by immunofluorescence on induced sputum or bronchoalveolar lavage (BAL) and/or a positive PCR assay on a BAL specimen. 17 The day the first positive clinical sample for Pneumocystis spp. was obtained was considered as the day of PJP diagnosis. For this study, baseline chronic renal insufficiency was defined as serum creatinine ≥1.5 mg/dL and/or requirement for he-
modialysis. Primary Pneumocystis-prophylaxis was defined as any
Pneumocystis-active prophylaxis initiated during the first 3 months post-transplant and administered for ≥7 days. Early-and late-onset PJP were defined as an infection diagnosed ≤ and >365 days posttransplant, respectively. CMV infection and disease were diagnosed based on prior published guidelines. 18, 19 Due to the small number of cases of CMV disease, CMV infection and disease were considered together in all analyses performed for the purposes of this study.
Acute rejection was defined for each organ following standard international guidelines. Figure 1A and Table 2 ).
| Statistical analysis
Incidence rate was significantly higher at center-2 (0.06/1000
person-days, 95% CI 0.04, 0.09) compared to all other centers (0.005, 95% CI 0.003, 0.008/1000 person-days; log-rank < 0.001; Figure 1B Figure 2D ). (Table 2) PJP occurred at a mean of 493 days (SD: 438, median: 363, range: 
| Pneumocystis prophylaxis
| Timing, Diagnosis and Treatment of PJP
67
| Risk factor analysis for PJP
Multivariable analyses on the overall patient population identified transplantation at center-2 (OR: 11.0, 95% CI 4.6, 26.1, P-value < 0.001) and kidney transplant (OR: 3.5, 95% CI 1.3, 9.3, P-value: 0.01) as significant risk factors for PJP (Table 3) . Considering the significantly more cases of PJP at center-2, separate risk factor analyses were performed for all other centers after excluding center-2 and for center-2 alone (Table 4) . When patients from center-2 were excluded, there was a trend for age ≥65 year (OR: 2.9, 
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| D ISCUSS I ON
In this large multicenter 8-year cohort of SOTr between 2008 and 2016 PJP remains a relatively rare event post-transplant with a wide time-distribution, depending on the administration of primary
Pneumocystis-prophylaxis.
Effective prophylaxis has significantly decreased the incidence of PJP in SOTr from 5%-15% to 0.3%-2.5% (1, 3, 6, 7, 9, 15). We of SOTr in this cohort did not receive Pneumocystis-prophylaxis.
Significantly higher rates of PJP occurring predominately during the first year post-transplant were observed in this patient-group.
The importance of Pneumocystis-prophylaxis was nicely illustrated in the case of center-2. During the first part of the study-period, PJP incidence was significantly higher at that center, where primary prophylaxis was not routinely administered. When prophylactic strategies changed to include >90% of SOTr, the incidence of PJP at center-2 rapidly dropped to the level of other centers. In an era, during which PJP-prophylaxis has become the standard of care, these data represent a valuable reminder of the importance of timely administration of effective Pneumocystis-prophylaxis in SOTr. Indeed, primary Pneumocystis-prophylaxis was identified as a protective factor against PJP in multivariable analyses, specifically for center-2 (Table 4) .
Consistent with prior reports, older age (particularly ≥65 yearold patients) emerged as a significant risk factor for PJP. 2,3,6,30 As previously described, CMV infection/disease was also identified as an independent predictor of PJP in multivariable analyses on the overall study population. 2, 3, 6, 7 However, the effect of CMV infection/disease on PJP was diluted in the separate analyses performed based on different SOT-centers (Table 4 ). There was a trend for administration of mTOR-inhibitors as maintenance immunosuppression during the first 6 months post-transplant as a predictor of PJP. A probable association between administration of sirolimus and infectious complications, including PJP, has been previously described. 10, [30] [31] [32] [33] This may, in part, be attributed to the impact of mTOR inhibition on T-and B-cell immunity. 34, 35 Moreover, a recently published meta-analysis suggested that administration of sirolimus may be associated with higher mortality rates due to infections in kidney transplant recipients. 36 Although intriguing, these observations need F I G U R E 2 Administration of Pneumocystis prophylaxis. A,Overall incidence of Pneumocystis jirovecii pneumonia (PJP) among 377 patients who did not receive primary Pneumocystis-prophylaxis (incidence rate 0.003%) compared to those who did (incidence rate 0.001%; log-rank < 0.001). B, One-year post-transplant incidence of PJP between patients who did and those who did not receive Pneumocystisprophylaxis (log-rank < 0.001). C, Duration of Pneumocystis-prophylaxis based on the type of transplanted organ presented as box-plots. D, Duration of Pneumocystis-prophylaxis during the first year post-transplant among different organ types
to be further investigated to make any more meaningful conclusions.
Lymphopenia has been previously identified as a significant predictor of PJP among SOTr. Considering the lower organism burden in HIV-negative patients with PJP, current guidelines recommend shorter treatment courses for SOTr with PJP (14-21 days). 4, 37 Most patients in this cohort received treatment with TMP-SMX for a duration of 21 days and co-administration of corticosteroids. As PJP has become a rare complication in SOTr, it is very unlikely that prospective, randomized The Pearson correlation coefficient identified possible correlations between (i) SOT-type and: age (r = 0.11, P-value < 0.001), SOT-center (r = 0.10, Pvalue < 0.001), mTOR-inhibitors (r = 0.18, P-value < 0.001), CMV infection/disease (r = 0.11, P-value < 0.001) and Pneumocystis-prophylaxis (r = 0.23, P-value < 0.001) and (ii) SOT-center and mTOR-inhibitor administration (r = 0.19, P-value < 0.001). In addition, administration of primary PJP prophylaxis (particularly for Center 2) changed during the study period. Hence, model-II was constructed, after excluding SOT-center, SOT-year, and SOT-type from independent variables.
TA B L E 4 Univariable and multivariable risk factor analyses for Pneumocystis jirovecii pneumonia in: (i) All centers, excluding center-2, and (ii) for center-2
All centers, excluding center-2
Center-2
Univariable analysis
Multivariable analysis
Univariable analysis A second multivariable analysis-II was performed after excluding the variables associated with SOT type and year, to avoid potential interactions between these independent variables and administration of prophylaxis.
clinical trials on the treatment of PJP in this patient population will be performed. Our data provide an update on real-life management of PJP in SOTr, suggesting that clinicians are more likely to use longer treatment courses and corticosteroids to treat SOTr with PJP. In contrast to previously reported high mortality rates (27%-60%) in HIV-negative immunocompromised patients with PJP, 1-year mortality was <15% in this cohort. 2, 4, 33, 38 This may reflect the progress attained in the field of PJP diagnosis, with the routine use of PCR and b-D-glucan at most centers, leading to earlier diagnosis and timely treatment initiation. In a small number of cases the diagnosis of PJP was solely based on PCR, with the potential for over-diagnosis of colonization. However, their treating physicians were convinced enough to treat these patients with full-courses of antibiotic treatment, frequently co-administered with corticosteroids.
Notably, one of the major limitations of the study was that the PCR cycle threshold (C t ) was not available for cases diagnosed based on a positive PCR, although only 4 cases were diagnosed based on a positive Pneumocystis PCR only. Finally, we were not able to exclude a possible outbreak at center-2, as molecular typing was performed but due to fragmented DNA results were non-interpretable.
In conclusion, in the Pneumocystis-prophylaxis era PJP appears to be 
